title: Pain in neurological conditions.
abstract: OBJECTIVE
  To address the issues of the scale and diversity of chronic pain in neurological disorders and the evidence for effective treatment of pain in these conditions.
  
  
  RESULTS
  Contemporary literature supports the notion that pain in neurological conditions is common and has tended to be underestimated.
  
  
  CONCLUSIONS
  Pain in neurological disease displays great diversity in putative mechanisms and clinical presentation. Rational management requires an analysis of likely mechanisms of pain generation as a guide to treatment. Some common neurological disorders are briefly discussed, primarily to provide an indication of the range of pain phenotypes observed across the spectrum of neurological disease. Treatments are reviewed with an emphasis on systemic drugs and the current best evidence for their use.
authors.affiliation: University College London Hospitals NHS Foundation Trust, London, UK. paul.nandi@uclh.nhs.uk
authors.forename: Paul R
authors.initials: PR
authors.lastname: Nandi
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D000779:Anesthetics, Local / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D002186:Cannabinoids / Q000627:therapeutic use; D059350:Chronic Pain / Q000188:drug therapy* / Q000503:physiopathology*; D020918:Complex Regional Pain Syndromes / Q000150:complications; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications; D009422:Nervous System Diseases / Q000150:complications*; D010300:Parkinson Disease / Q000150:complications; D010523:Peripheral Nervous System Diseases / Q000150:complications; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D020521:Stroke / Q000150:complications
chemical_list: D000700:Analgesics; D000779:Anesthetics, Local; D000927:Anticonvulsants; D000928:Antidepressive Agents; D002186:Cannabinoids; D016194:Receptors, N-Methyl-D-Aspartate